Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a clinical stage biopharmaceutical company with a strong portfolio focused on Precision Medicine for neurodegenerative diseases, which has been actively expanding its pipeline with programs strategically targeting protein misfolding in neurodegenerative diseases. Compared to mAbs, AC Immune's vaccines have several advantages including reduced cost, longer-lasting responses, and simpler injections, providing a versatile platform for the development of both small molecule imaging agents and oral anti-aggregation agents. With solid financials and a strong focus on the development of innovative treatments, AC Immune appears to be in a good position to continue its growth as a leading player in the neurodegenerative disease space.

Bears say

AC Immune is currently focused on developing therapeutic and diagnostic products for neurodegenerative diseases through its proprietary technology platforms. However, as a financial analyst, one should consider the company's heavy reliance on just one segment and potential competition from larger and more established pharmaceutical companies. Additionally, while the company's partnership with Takeda may bring in milestone payments and royalties, it also limits the company's decision-making and potential profits. With a negative outlook, it is important to closely monitor AC Immune's clinical trial results and potential shifts in the market for neurodegenerative disease treatments.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.